logo.png
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
28. Dezember 2022 07:00 ET | BIOXYTRAN, INC.
Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...